Entering text into the input field will update the search result below

Rock Creek Pharma announces positive study results for lead product candidate; shares up 15%

  • Thinly traded nano cap Rock Creek Pharmaceuticals (OTC:RCPI-OLD +15.1%) jumps on a 5x surge in volume in response to its announcement of positive results of a 10-subject human proof-of-principle study of its lead product candidate, anatabine citrate. Results showed that a single oral dose can significantly inhibit the activation of inflammatory proteins in human white blood cells.
  • A Phase 1 trial is being planned in the UK.
  • Anatabine citrate is a small molecule cholinergic (refers to the neurotransmitter acetylcholine) agonist which exhibits anti-inflammatory pharmacological characteristics. Its mechanism of action is different than other anti-inflammatory drugs such as biologics and steroids.

Recommended For You

Related Stocks

SymbolLast Price% Chg
RCPI-OLD--
Rock Creek Pharmaceuticals, Inc.